• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组织化学作为 NTRK 基因融合的筛查工具:一项首次比利时环试验的结果。

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.

机构信息

Laboratory of Pathological Anatomy, Antwerp University Hospital (UZA), 2650, Edegem, Belgium.

Center for Oncological Research Antwerp (CORE), University of Antwerp (UAntwerp), 2610, Wilrijk, Belgium.

出版信息

Virchows Arch. 2021 Feb;478(2):283-291. doi: 10.1007/s00428-020-02921-6. Epub 2020 Sep 11.

DOI:10.1007/s00428-020-02921-6
PMID:32915263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7969564/
Abstract

A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2 fusion positive and 2 samples with wild-type endogenous TRK expression. Each participating laboratory stained the slides using their routine pan-TRK IHC and reported their results. In addition, they were asked to return one TRK-stained slide from each case. The coordinating lab evaluated these slides, compared them with the reference method and scored them. Two clones were used during the ring trial: A7H6R (Cell Signaling) and EPR17341 (Abcam/Ventana). Seven protocols achieved a sufficient performance mark, and three labs were advised to further optimise the protocol. Interpretation of pan-TRK IHC proved to be challenging in cases with physiological TRK expression. In addition, depending on the NTRK fusion partner, the staining can vary strongly in both intensity and staining pattern. Labs using the Ventana ready-to-use system based on the EPR17341 clone and using the recommended protocol settings scored best. However, given some small optimisation, all labs scored well on the technical staining and the succeeding evaluation.

摘要

一项针对泛 TRK 免疫组织化学(IHC)染色的比利时环试验旨在协调泛 TRK IHC 染色方案和解释。作为参考方法,选择了VENTANA pan-TRK 检测(克隆 EPR17341)在 Benchmark Ultra 平台上。选择了 6 个样本:2 个阴性、2 个融合阳性和 2 个具有野生型内源性 TRK 表达的样本。每个参与实验室使用其常规的泛 TRK IHC 染色这些幻灯片,并报告他们的结果。此外,他们被要求从每个病例中返回一张 TRK 染色的幻灯片。协调实验室对这些幻灯片进行评估,与参考方法进行比较并对其进行评分。在环试验中使用了两种克隆:A7H6R(Cell Signaling)和 EPR17341(Abcam/Ventana)。七种方案达到了足够的性能标记,三个实验室被建议进一步优化方案。具有生理 TRK 表达的病例中,泛 TRK IHC 的解释证明具有挑战性。此外,根据 NTRK 融合伙伴的不同,染色在强度和染色模式上都可能有很大差异。使用基于 EPR17341 克隆的 Ventana 即用型系统且使用推荐方案设置的实验室得分最高。然而,鉴于一些小的优化,所有实验室在技术染色和随后的评估中都取得了很好的成绩。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/7969564/bcf908338f1c/428_2020_2921_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/7969564/9d451021ff23/428_2020_2921_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/7969564/bcf908338f1c/428_2020_2921_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/7969564/9d451021ff23/428_2020_2921_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/7969564/bcf908338f1c/428_2020_2921_Fig2_HTML.jpg

相似文献

1
Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.免疫组织化学作为 NTRK 基因融合的筛查工具:一项首次比利时环试验的结果。
Virchows Arch. 2021 Feb;478(2):283-291. doi: 10.1007/s00428-020-02921-6. Epub 2020 Sep 11.
2
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.泛Trk免疫组化是检测NTRK融合的一种有效且可靠的筛查方法。
Am J Surg Pathol. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911.
3
A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.多种癌症类型中泛Trk免疫组化检测的系统比较。
Histopathology. 2023 Jun;82(7):1003-1012. doi: 10.1111/his.14884. Epub 2023 Feb 22.
4
Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.多中心泛 Trk 免疫组化检测 NTRK3 融合的协同研究。
Mod Pathol. 2023 Aug;36(8):100192. doi: 10.1016/j.modpat.2023.100192. Epub 2023 Apr 20.
5
EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.EPR17341 和 A7H6R 泛 TRK 免疫组化在一系列唾液腺肿瘤中呈现高度不同的染色模式。
Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):719-724. doi: 10.1097/PAI.0000000000000825.
6
Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.加拿大多中心泛 TRK(CANTRK)免疫组织化学协调研究。
Mod Pathol. 2024 Jan;37(1):100384. doi: 10.1016/j.modpat.2023.100384. Epub 2023 Nov 14.
7
Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.使用泛TRK免疫组织化学和RNA二代测序融合检测板对NTRK基因融合进行泛肿瘤筛查。
Cancer Genet. 2022 Apr;262-263:47-52. doi: 10.1016/j.cancergen.2021.12.010. Epub 2022 Jan 2.
8
Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.胶质母细胞瘤中 NTRK 融合的检测:荧光原位杂交比 pan-TRK 免疫组化作为 RNA 测序前的筛选工具更有用。
Pathology. 2022 Feb;54(1):55-62. doi: 10.1016/j.pathol.2021.05.100. Epub 2021 Sep 10.
9
Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.泛-Trk 免疫组化鉴定儿科间叶性肿瘤中的 NTRK 重排。
Am J Surg Pathol. 2018 Jul;42(7):927-935. doi: 10.1097/PAS.0000000000001062.
10
Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.预测性“生物标志物搭载”:一项关于采用泛TRK免疫组化进行反射性泛癌筛查的研究。
Histopathology. 2021 Aug;79(2):260-264. doi: 10.1111/his.14351. Epub 2021 Apr 7.

引用本文的文献

1
Oncogenic gene fusions in cancer: from biology to therapy.癌症中的致癌基因融合:从生物学至治疗
Signal Transduct Target Ther. 2025 Apr 14;10(1):111. doi: 10.1038/s41392-025-02161-7.
2
NTRK protein expression in NSCLC and its clinicopathological correlation.非小细胞肺癌中NTRK蛋白表达及其临床病理相关性。
Histol Histopathol. 2025 Oct;40(10):1569-1576. doi: 10.14670/HH-18-894. Epub 2025 Feb 26.
3
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.NTRK融合的中枢神经系统肿瘤:临床病理与遗传学见解及对TRK抑制剂的反应

本文引用的文献

1
EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.EPR17341 和 A7H6R 泛 TRK 免疫组化在一系列唾液腺肿瘤中呈现高度不同的染色模式。
Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):719-724. doi: 10.1097/PAI.0000000000000825.
2
Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.中枢神经系统肿瘤中的融合基因:一种罕见但值得关注的靶点。
Int J Mol Sci. 2020 Jan 23;21(3):753. doi: 10.3390/ijms21030753.
3
NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
Acta Neuropathol Commun. 2024 Jul 16;12(1):118. doi: 10.1186/s40478-024-01798-9.
4
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.泛 TRK 免疫组化的验证和解读:一种实用方法及解读挑战。
Diagn Pathol. 2024 Jan 10;19(1):10. doi: 10.1186/s13000-023-01426-5.
5
Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors.巴西实体瘤中NTRK基因融合检测专家共识
Clin Pathol. 2023 Sep 15;16:2632010X231197080. doi: 10.1177/2632010X231197080. eCollection 2023 Jan-Dec.
6
Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects.肉瘤系列中的融合:病理学、分子和临床方面。
Pathol Oncol Res. 2022 May 11;28:1610423. doi: 10.3389/pore.2022.1610423. eCollection 2022.
7
Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.推荐用于儿科和部分成人癌症中 NTRK 基因融合检测的算法:新加坡专家组共识。
Asia Pac J Clin Oncol. 2022 Aug;18(4):394-403. doi: 10.1111/ajco.13727. Epub 2021 Nov 21.
8
Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects.肉瘤中的融合基因:诊断挑战与临床方面
Diagnostics (Basel). 2021 Mar 9;11(3):478. doi: 10.3390/diagnostics11030478.
NTRK 基因重排在 MLH1/PMS2 缺陷、BRAF 野生型结直肠癌中高度富集——一项 4569 例病例研究。
Mod Pathol. 2020 May;33(5):924-932. doi: 10.1038/s41379-019-0417-3. Epub 2019 Dec 2.
4
Identifying patients with NTRK fusion cancer.鉴定具有 NTRK 融合癌症的患者。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22. doi: 10.1093/annonc/mdz384.
5
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.原肌球蛋白受体激酶(TRK)生物学和 NTRK 基因融合在癌症中的作用。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii5-viii15. doi: 10.1093/annonc/mdz383.
6
Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.Pan-Trk 免疫组化可靠地鉴定唾液腺癌中的 ETV6-NTRK3 融合。
Virchows Arch. 2020 Feb;476(2):295-305. doi: 10.1007/s00428-019-02640-7. Epub 2019 Aug 19.
7
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.检测多种检测方法和 33997 例中的 NTRK 融合:诊断意义和陷阱。
Mod Pathol. 2020 Jan;33(1):38-46. doi: 10.1038/s41379-019-0324-7. Epub 2019 Aug 2.
8
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.ESMO 关于在日常实践和临床研究中检测 NTRK 融合的标准方法的建议。
Ann Oncol. 2019 Sep 1;30(9):1417-1427. doi: 10.1093/annonc/mdz204.
9
Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms.融合基因检测:当前诊断平台的优缺点。
Cancer Res. 2019 Jul 1;79(13):3163-3168. doi: 10.1158/0008-5472.CAN-19-0372. Epub 2019 Jun 13.
10
Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence.拉罗替尼在携带基因融合的肿瘤中的抗肿瘤活性:当前证据的简要综述
Onco Targets Ther. 2019 Apr 30;12:3171-3179. doi: 10.2147/OTT.S177051. eCollection 2019.